Explore the Potential with AI-Driven Innovation
The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.
The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by our partner Reaxense.
The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.
We employ our advanced, specialised process to create targeted libraries.
Fig. 1. The sreening workflow of Receptor.AI
Our methodology employs molecular simulations to explore a wide array of proteins, capturing their dynamic states both individually and within complexes. Through ensemble virtual screening, we address conformational mobility, uncovering binding sites within functional regions and remote allosteric locations. This thorough exploration ensures no potential mechanism of action is overlooked, aiming to discover novel therapeutic targets and lead compounds across an extensive spectrum of biological functions.
Key features that set our library apart include:
partner
Reaxense
upacc
Q6PI26
UPID:
SHQ1_HUMAN
Alternative names:
-
Alternative UPACC:
Q6PI26; B4DL05; Q6MZJ4; Q7Z748; Q9H7E5; Q9NVS8
Background:
Protein SHQ1 homolog plays a crucial role in the assembly and stability of H/ACA ribonucleoproteins (RNPs), including telomerase. This process is vital for the maintenance of telomere length, implicating SHQ1 in cellular aging and proliferation.
Therapeutic significance:
Given its involvement in dystonia 35 and neurodevelopmental disorders, targeting SHQ1 could offer new avenues for therapeutic interventions in these debilitating conditions. Understanding the role of Protein SHQ1 homolog could open doors to potential therapeutic strategies.